WallStreetZenWallStreetZen

NASDAQ: INZY
Inozyme Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for INZY

Based on 6 analysts offering 12 month price targets for Inozyme Pharma Inc

Min Forecast
$4.00+0.25%
Avg Forecast
$14.83+271.75%
Max Forecast
$30.00+651.88%

Should I buy or sell INZY stock?

Based on 6 analysts offering ratings for Inozyme Pharma Inc.

Buy
Strong Buy
2 analysts 33.33%
Buy
1 analysts 16.67%
Hold
3 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their INZY stock forecasts and price targets.

INZY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-16
lockedlocked$00.00+00.00%2025-05-16
lockedlocked$00.00+00.00%2025-05-16
lockedlocked$00.00+00.00%2025-04-10
lockedlocked$00.00+00.00%2025-03-11
Piper Sandler
Bottom 6%
6
Strong BuyMaintains$30.00+651.88%2025-01-13

1 of 1

Forecast return on equity

Is INZY forecast to generate an efficient return?

Company
13.54%
Industry
140.91%
Market
90.47%
INZY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INZY forecast to generate an efficient return on assets?

Company
4.53%
Industry
32.45%
INZY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INZY earnings per share forecast

What is INZY's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$1.41
Avg 2 year Forecast
-$1.21
Avg 3 year Forecast
-$0.63

INZY revenue forecast

What is INZY's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$7.4M
Avg 2 year Forecast
$55.1M
Avg 3 year Forecast
$180.2M

INZY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INZY$3.99$14.83+271.75%Buy
CADL$5.13$21.00+309.36%Strong Buy
NBTX$5.35$8.00+49.67%Strong Buy
CRDF$3.81$18.00+372.44%Buy
IMMP$1.74N/AN/A
View Top Biotech Stocks

Inozyme Pharma Stock Forecast FAQ

Is Inozyme Pharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: INZY) stock is to Buy INZY stock.

Out of 6 analysts, 2 (33.33%) are recommending INZY as a Strong Buy, 1 (16.67%) are recommending INZY as a Buy, 3 (50%) are recommending INZY as a Hold, 0 (0%) are recommending INZY as a Sell, and 0 (0%) are recommending INZY as a Strong Sell.

If you're new to stock investing, here's how to buy Inozyme Pharma stock.

What is INZY's earnings growth forecast for 2025-2027?

(NASDAQ: INZY) Inozyme Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Inozyme Pharma's earnings in 2025 is -$106,716,000.On average, 7 Wall Street analysts forecast INZY's earnings for 2025 to be -$90,844,943, with the lowest INZY earnings forecast at -$105,881,391, and the highest INZY earnings forecast at -$74,891,716. On average, 7 Wall Street analysts forecast INZY's earnings for 2026 to be -$78,029,420, with the lowest INZY earnings forecast at -$96,842,736, and the highest INZY earnings forecast at -$49,066,986.

In 2027, INZY is forecast to generate -$40,415,702 in earnings, with the lowest earnings forecast at -$85,221,608 and the highest earnings forecast at $9,038,655.

What is INZY's revenue growth forecast for 2026-2028?

(NASDAQ: INZY) Inozyme Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Inozyme Pharma's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast INZY's revenue for 2026 to be $478,403,116, with the lowest INZY revenue forecast at $478,403,116, and the highest INZY revenue forecast at $478,403,116. On average, 4 Wall Street analysts forecast INZY's revenue for 2027 to be $3,556,194,390, with the lowest INZY revenue forecast at $1,078,828,079, and the highest INZY revenue forecast at $8,899,847,438.

In 2028, INZY is forecast to generate $11,634,040,685 in revenue, with the lowest revenue forecast at $6,968,157,664 and the highest revenue forecast at $16,299,923,705.

What is INZY's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: INZY) forecast ROA is 4.53%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is INZY's Price Target?

According to 6 Wall Street analysts that have issued a 1 year INZY price target, the average INZY price target is $14.83, with the highest INZY stock price forecast at $30.00 and the lowest INZY stock price forecast at $4.00.

On average, Wall Street analysts predict that Inozyme Pharma's share price could reach $14.83 by May 16, 2026. The average Inozyme Pharma stock price prediction forecasts a potential upside of 271.75% from the current INZY share price of $3.99.

What is INZY's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: INZY) Inozyme Pharma's current Earnings Per Share (EPS) is -$1.69. On average, analysts forecast that INZY's EPS will be -$1.41 for 2025, with the lowest EPS forecast at -$1.64, and the highest EPS forecast at -$1.16. On average, analysts forecast that INZY's EPS will be -$1.21 for 2026, with the lowest EPS forecast at -$1.50, and the highest EPS forecast at -$0.76. In 2027, INZY's EPS is forecast to hit -$0.63 (min: -$1.32, max: $0.14).

What is INZY's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: INZY) forecast ROE is 13.54%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.